ANALYSIS OF COMBINED INFLUENCE OF INTRATUMORAL EXPRESSION OF TS AND HENT1 ON EFFICACY OF GEMCITABINE+TEGAFUR ADJUVANT TREATMENT OF PATIENTS WITH PANCREATIC CANCER

Authors

  • O. I. Dronov O. Bohomolets National Medical University, Kyiv
  • S. V. Zemskov O. Bohomolets National Medical University, Kyiv
  • O. M. Hrabovyy National Cancer Institute
  • I. S. Klymnyuk V. Zemskov Kyiv Centre of Surgery of the Liver, Bile ducts and Pancreas

DOI:

https://doi.org/10.11603/2415-8798.2016.4.7139

Keywords:

pancreatic cancer, adjuvant chemotherapy, gemcitabine, tegafur, hENT1, TS, overall survival, chemosensititvity.

Abstract

Pancreatic cancer (PC) is one of the most aggressive gastrointestinal cancers. Only curative resection gives a chance for long-term survival which is still unacceptably low. Optimizing of adjuvant for PC treatment is timely in modern oncology. The aim of the sudy is combined analysis of TS and hENT1 intratumoral expression influence on overall survival (OS) in patients with PC treated with gemcitabine+tegafur (GemTeg) in adjuvant setting. 62 R0-resected patients with I-II UICC stage of PC were involved in the retrospective study. All patietns were adjuvantly treated with GemTeg (6 x 28-day cycles). Diagnosis was verified histologically as ductal adenocarcinoma. Afterwards TS and hENT1 expression was investigated immunohistochemically. Statistical calculation was performed by means of Chi square, exact Fisher, Kaplan-Meyer tests and Cox’s analysis. Median follow-up was 34 months. OS benefit was evaluated in comparison to cohort of patients with both low hENT1 and TS expression by univariate analysis. OS in cohorts of patients with high hENT1, high TS and combination of high hENT1 and TS was markedly higher (р=0.053; р=0.03 and р<0.001 respectively). In multivariate Cox’s analysis for stratified cohorts HR was 4.65 (СI: 2.12–10.21), 4.82 (СI: 2.13–10.91) та 23,14 (СI: 2.73–195.88) respectively. High intratumoral expression of hENT1 and TS may independently improve OS in PC patients treated with GemTeg in adjuvant setting. Patietns with combination high hENT1 and TS expression benefitted mostly according to GemTeg adjuvant therapy.

References

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial / J. P. Neoptolemos, D. D. Stocken, C. Bassi [et al.] // JAMA. – 2010. – Vol. 304. – P. 1073–1081.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer / D. Cunningham, I. Chau, D. D. Stocken [et al.] // J. Clin. Oncol. – 2009. – Vol. 27. – P. 5513–5518.

Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma / Y. Murakami, K. Uemura, T. Sudo [et al.] // Am. J. Surg. – 2008. – Vol. 195. – P. 757–762.

Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas / Y. Murakami, K. Uemura, T. Sudo [et al.] // J. Gastrointest. Surg. – 2009. – Vol. 13. – P. 85–92.

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine / E. Giovannetti, M. Del Tacca, V. Mey [et al.] // Cancer Res. – 2006. – Vol. 66. – P. 3928–3935.

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer / J. J. Farrell, H. Elsaleh, M. Garcia [et al.] // Gastroenterology. – 2009. – Vol. 136. – P. 187–195.

Thymidylate synthase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil / S. P. Spears, B. G. Gustavsson, M. S. Mitchell [et al.] // Cancer Res. – 1984. – Vol. 44. – P. 4144–4150.

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil / Peters G. J., C. L.van der Wilt, C. J. van Groeningen [et al.] // J. Clin. Oncol. – 1994. – Vol. 12. – P. 2035–2042.

Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives / M. Takamura, Y. Nio, K. Yamasawa [et al.] // Anti-Cancer Drugs – 2002. – Vol. 13. – P. 75–85.

Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer / Y.C. Hu, R. A. Komorowski, S. Graewin [et al.] // Clinical Cancer Research. – 2003. – Vol. 9. – P. 4165–4171.

Downloads

Published

2017-02-09

How to Cite

Dronov, O. I., Zemskov, S. V., Hrabovyy, O. M., & Klymnyuk, I. S. (2017). ANALYSIS OF COMBINED INFLUENCE OF INTRATUMORAL EXPRESSION OF TS AND HENT1 ON EFFICACY OF GEMCITABINE+TEGAFUR ADJUVANT TREATMENT OF PATIENTS WITH PANCREATIC CANCER. Bulletin of Scientific Research, (4). https://doi.org/10.11603/2415-8798.2016.4.7139

Issue

No. 4 (2016)

Section

INTERNAL MEDICINE

License

Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Результат пошуку зображень за запитом "CC-BY logo"         

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)